Grace Therapeutics, Inc expected to post a loss of 22 cents a share - Earnings Preview

Grace Therapeutics

07/08/2025 20:02

Grace Therapeutics, Inc GRCE.OQ GRCE.O is expected to  show no change in quarterly revenue when it reports  results on August 9 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Grace Therapeutics, Inc is for a loss of 22 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Grace Therapeutics, Inc is $12.00, about 75.3% above its last closing price of $2.97

This summary was machine generated August 7 at 19:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)